5mg vial tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Zepbound 12.5 mg/0.5 mL injection

These improvements include lowering the risk of cardiovascular disease and enhancing overall metabolic health

the excess is converted to glucose or burned for energy rather than helping preserve muscle

Testosterone, by contrast, is a well-established, licensed therapy used for confirmed hypogonadism and gender-affirming care under specialist supervision

These treatments benefit patients looking for a non-surgical weight loss solution that can be combined with lifestyle changes

However, tirzepatide may have a slightly higher rate of gastrointestinal side effects due to its dual mechanism targeting both GLP-1 and GIP receptors

Cung cp m cn thit, gip da tay lun mm mi